IRTC Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of -31.3% compared to iRhythm Technologies's net margin of 11.12%. iRhythm Technologies's return on equity of -108.99% beat Boston Scientific's return on equity of 8.91%.

iRhythm Technologies has a consensus price target of $100.92, signalling upside risk potential of 16.26%. On the other hand Boston Scientific has an analysts' consensus of $99.42 which suggests that it could grow by 9.62%. Given that iRhythm Technologies has higher upside potential than Boston Scientific, analysts believe iRhythm Technologies is more attractive than Boston Scientific.

iRhythm Technologies has a beta of 1.257, which suggesting that the stock is 25.744% more volatile than S&P 500. In comparison Boston Scientific has a beta of 0.800, suggesting its less volatile than the S&P 500 by 20.007%.

iRhythm Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iRhythm Technologies pays -- of its earnings as a dividend. Boston Scientific pays out 1.76% of its earnings as a dividend. Boston Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

iRhythm Technologies quarterly revenues are $147.5M, which are smaller than Boston Scientific quarterly revenues of $4.2B. iRhythm Technologies's net income of -$46.2M is lower than Boston Scientific's net income of $468M. Notably, iRhythm Technologies's price-to-earnings ratio is -- while Boston Scientific's PE ratio is 74.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iRhythm Technologies is 5.03x versus 8.45x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics has a net margin of -31.3% compared to iRhythm Technologies's net margin of --. iRhythm Technologies's return on equity of -108.99% beat Perspective Therapeutics's return on equity of --.

iRhythm Technologies has a consensus price target of $100.92, signalling upside risk potential of 16.26%. On the other hand Perspective Therapeutics has an analysts' consensus of $16.15 which suggests that it could grow by 360.11%. Given that Perspective Therapeutics has higher upside potential than iRhythm Technologies, analysts believe Perspective Therapeutics is more attractive than iRhythm Technologies.

iRhythm Technologies has a beta of 1.257, which suggesting that the stock is 25.744% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.195, suggesting its more volatile than the S&P 500 by 19.546%.

iRhythm Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iRhythm Technologies pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

iRhythm Technologies quarterly revenues are $147.5M, which are larger than Perspective Therapeutics quarterly revenues of --. iRhythm Technologies's net income of -$46.2M is lower than Perspective Therapeutics's net income of -$15.1M. Notably, iRhythm Technologies's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iRhythm Technologies is 5.03x versus 18.95x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -31.3% compared to iRhythm Technologies's net margin of -4291.67%. iRhythm Technologies's return on equity of -108.99% beat Catheter Precision's return on equity of -65.84%.

iRhythm Technologies has a consensus price target of $100.92, signalling upside risk potential of 16.26%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 277.36%. Given that Catheter Precision has higher upside potential than iRhythm Technologies, analysts believe Catheter Precision is more attractive than iRhythm Technologies.

iRhythm Technologies has a beta of 1.257, which suggesting that the stock is 25.744% more volatile than S&P 500. In comparison Catheter Precision has a beta of -0.184, suggesting its less volatile than the S&P 500 by 118.441%.

iRhythm Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iRhythm Technologies pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

iRhythm Technologies quarterly revenues are $147.5M, which are larger than Catheter Precision quarterly revenues of $96K. iRhythm Technologies's net income of -$46.2M is lower than Catheter Precision's net income of -$4.1M. Notably, iRhythm Technologies's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iRhythm Technologies is 5.03x versus 1.41x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -31.3% compared to iRhythm Technologies's net margin of -17.98%. iRhythm Technologies's return on equity of -108.99% beat Xtant Medical Holdings's return on equity of -35.98%.

iRhythm Technologies has a consensus price target of $100.92, signalling upside risk potential of 16.26%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 326.95%. Given that Xtant Medical Holdings has higher upside potential than iRhythm Technologies, analysts believe Xtant Medical Holdings is more attractive than iRhythm Technologies.

iRhythm Technologies has a beta of 1.257, which suggesting that the stock is 25.744% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.673%.

iRhythm Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iRhythm Technologies pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

iRhythm Technologies quarterly revenues are $147.5M, which are larger than Xtant Medical Holdings quarterly revenues of $27.9M. iRhythm Technologies's net income of -$46.2M is lower than Xtant Medical Holdings's net income of -$5M. Notably, iRhythm Technologies's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iRhythm Technologies is 5.03x versus 0.61x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.